The relationship between the combined use of various proton pump inhibitors with antiplatelet drugs and the risk of cardiovascular complications
Остроумова О. Д., Кочетков А. И., Переверзев А. П., Кравченко Е. В., Казйулин А. Н., Андреев Д. Н., Павлеева Е. Е.
Терапевтический архив
Т. 91, Вып. 8, С. 118-126
Опубликовано: 2019
Тип ресурса: Статья
DOI:10.26442/00403660.2019.08.000355
Аннотация:
In the article the problem of the combined use of clopidogrel and various proton pump inhibitors (PPIs) in terms of cardiovascular complications risk and stent thrombosis is considered. The results of meta-analyses and a systematic reviews affecting this issue are represented in detail. The inter-drug interactions mechanisms of various PPIs with clopidogrel based on the characteristics of the metabolism in the liver cytochromes system are discussed. The authors conducted a search, systematization and analysis of studies regarding the association between cardiovascular risk and combined use of individual medications from PPI class with clopidogrel, and these results are presented in the review. Currently available data do not allow to answer the question about the differences between individual PPIs in their impact on the risk of adverse cardiovascular events due to the small number of such studies, design heterogeneity, differences in the inclusion criteria and end points as well as in
Ключевые слова:
Adverse cardiovascular outcomes; Clopidogrel; Coronary artery disease; Drug interaction; Dual antiplatelet therapy; Percutaneous coronary intervention; Proton pump inhibitor
antithrombocytic agent; clopidogrel; proton pump inhibitor; ticlopidine; cardiovascular disease; combination drug therapy; drug interaction; human; meta analysis; treatment outcome; Cardiovascular Diseases; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Proton Pump Inhibitors; Ticlopidine; Treatment Outcome
Язык текста: Русский
ISSN: 2309-5342
Остроумова О. Д. Ольга Дмитриевна 1968-
Кочетков А. И.
Переверзев А. П.
Кравченко Е. В.
Казйулин А. Н.
Андреев Д. Н.
Павлеева Е. Е.
Ostroumova O. D. Ol`ga Dmitrievna 1968-
Kochetkov A. I.
Pereverzev A. P.
Kravchenko E. V.
Kazjulin A. N.
Andreev D. N.
Pavleeva E. E.
The relationship between the combined use of various proton pump inhibitors with antiplatelet drugs and the risk of cardiovascular complications
Текст визуальный непосредственный
Терапевтический архив
Медицинское маркетинговое агентство "МедиаМедика"
Т. 91, Вып. 8 С. 118-126
2019
Статья
Adverse cardiovascular outcomes Clopidogrel Coronary artery disease Drug interaction Dual antiplatelet therapy Percutaneous coronary intervention Proton pump inhibitor
antithrombocytic agent clopidogrel proton pump inhibitor ticlopidine cardiovascular disease combination drug therapy drug interaction human meta analysis treatment outcome Cardiovascular Diseases Clopidogrel Drug Interactions Drug Therapy, Combination Humans Platelet Aggregation Inhibitors Proton Pump Inhibitors Ticlopidine Treatment Outcome
In the article the problem of the combined use of clopidogrel and various proton pump inhibitors (PPIs) in terms of cardiovascular complications risk and stent thrombosis is considered. The results of meta-analyses and a systematic reviews affecting this issue are represented in detail. The inter-drug interactions mechanisms of various PPIs with clopidogrel based on the characteristics of the metabolism in the liver cytochromes system are discussed. The authors conducted a search, systematization and analysis of studies regarding the association between cardiovascular risk and combined use of individual medications from PPI class with clopidogrel, and these results are presented in the review. Currently available data do not allow to answer the question about the differences between individual PPIs in their impact on the risk of adverse cardiovascular events due to the small number of such studies, design heterogeneity, differences in the inclusion criteria and end points as well as in